TSVT241115C5000
- 0.45
- -0.05-10.00%
2seventy bio Newsroom
TD Cowen Maintains 2seventy Bio(TSVT.US) With Hold Rating
Leerink Partners Maintains 2seventy Bio(TSVT.US) With Buy Rating, Announces Target Price $15
Buy Rating Affirmed for 2seventy Bio Despite Trial Setback: Niche Market Strategy and Safety Profile Underpin Positive Outlook
Morgan Stanley Maintains 2seventy Bio(TSVT.US) With Hold Rating, Maintains Target Price $6
Hold Rating on 2seventy Bio Amidst Strategic Shifts and Enrollment Challenges
Analysts' Opinions Are Mixed on These Healthcare Stocks: Walgreens Boots Alliance (WBA), 2seventy Bio (TSVT) and Repare Therapeutics (RPTX)
Morgan Stanley Maintains 2seventy Bio(TSVT.US) With Hold Rating, Maintains Target Price $6
Analysts Offer Insights on Healthcare Companies: 2seventy Bio (TSVT), Illumina (ILMN) and Larimar Therapeutics (LRMR)
Leerink Partners Keeps Their Buy Rating on 2seventy Bio (TSVT)
Hold Rating on 2seventy Bio: Balancing Modest Sales Growth Against Competitive Market Pressures
2seventy Bio Price Target Cut to $6.00/Share From $7.00 by Morgan Stanley
2seventy Bio Analyst Ratings
Morgan Stanley Maintains Equal-Weight on 2seventy Bio, Lowers Price Target to $6
Morgan Stanley Maintains 2seventy Bio(TSVT.US) With Hold Rating, Cuts Target Price to $6
Analysts Offer Insights on Healthcare Companies: 2seventy Bio (TSVT) and Abbott Laboratories (ABT)
2seventy Bio Analyst Ratings
Wedbush Reiterates Neutral on 2seventy Bio, Maintains $5 Price Target
Buy Rating Affirmed for 2seventy Bio on Strong Growth Prospects and Financial Stability
Canadian Investment Banking Group: Maintaining the 2seventy bio (TSVT.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $12.00 to $11.00.
2seventy Bio Analyst Ratings